Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445322 · ClinicalTrials.gov registry record
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
A clinical trial of Stargardt Disease and Cone-Rod Dystrophy, sponsored by Ascidian Therapeutics.
- Recruiting
- Registry status
- 50
- Enrollment target
- 8
- Study locations
NCT06445322: Recruiting study of Stargardt Disease and Cone-Rod Dystrophy, sponsored by Ascidian Therapeutics.
NCT06445322 is a study of Stargardt Disease and Cone-Rod Dystrophy that is actively recruiting participants, run by Ascidian Therapeutics. The registered enrollment target is 50 participants, below the 88-participant average among 16 other Stargardt Disease trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06445322, a study of Stargardt Disease and Cone-Rod Dystrophy, is actively recruiting participants, sponsored by Ascidian Therapeutics.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Primary Outcome
Using a Clinical Laboratory Improved Amendments (CLIA)-certified laboratory.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Prescreening Assessments
Study Locations (8)
Texas
- Retina Foundation of Texas - Dallas
- Retina Consultants of Texas - Houston
California
- University of San Francisco - San Francisco
Florida
- Vitreo Retinal Associates - Gainesville
Maryland
- Wilmer Eye Institute at John Hopkins - Baltimore
Massachusetts
- Massachusetts Eye and Ear - Boston
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Ohio
- Cincinnati Eye Institute - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2030-08-31 |
What NCT06445322 shows while recruiting
NCT06445322 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 88-participant average among 16 other Stargardt Disease trials with a reported enrollment target (43% lower).
The record links to 4 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which Prescreening Assessments is the first listed.
NCT06445322 lists 8 locations in 7 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06445322 about?
NCT06445322 is a clinical study titled "Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)". This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
What is the current status of trial NCT06445322?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-06-20. Estimated completion is 2030-08-31.
What conditions does trial NCT06445322 study?
This clinical trial studies the following conditions: Stargardt Disease, Cone-Rod Dystrophy, Stargardt Disease 1, Juvenile Macular Degeneration.
What interventions are being tested in trial NCT06445322?
The interventions under investigation include: Prescreening Assessments (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06445322?
This trial is sponsored by Ascidian Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445322 being conducted?
This trial has 8 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06445322's enrollment target sits among peer trials
50 11th of 16 higher than 6 of 16 other Stargardt Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stargardt Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI